


See "Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies" on page 475-486.



**Supplementary Fig. 3.** Sustained clinical remission at weeks 36, 40, and 44 of the maintenance study. <sup>a</sup> $P=0.023$  vs. placebo; <sup>b</sup> $P<0.001$  vs. placebo. q12w, every 12 weeks; q8w, every 8 weeks.